BLA 125370 · Human Genome Sciences Inc.
Benlysta
Belimumab · Injection · B Lymphocyte Stimulator-specific Inhibitor
NovelBreakthrough therapyPriority reviewLast checked: Nov 20, 2026Latest source record: Oct 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Mar 9, 2011
Approved uses
6
Original approval plus efficacy supplements
Registered trials
86
20 Phase 3, 18 recruiting
FAERS reports
32,030
13,657 serious, 907 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 30, 2026.
BENLYSTA is indicated for the treatment of patients 5 years of age and older with: • Active systemic lupus erythematosus (SLE) who are receiving standard therapy, and • Active lupus nephritis who are receiving standard therapy. Limitations of Use The efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system (CNS) lupus. Use of BENLYSTA is not recommended in this situation. BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of patients 5 years of age and older with: • Active systemic lupus erythematosus (SLE) who are receiving standard therapy; ( 1 ) • Active lupus nephritis who are receiving standard therapy. ( 1 ) Limitations of Use: The efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system lupus. Use of BENLYSTA is not recommended in this situation. ( 1 )
Mechanism: BENLYSTA is a BLyS-specific inhibitor that blocks the binding of soluble BLyS, a B-cell survival factor, to its receptors on B cells. BENLYSTA does not bind B cells directly, but by binding BLyS, BENLYSTA inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 26, 2022 Supplement 78 · Efficacy · priority review Letter
- Dec 16, 2020 Supplement 73 · Efficacy · priority review Breakthrough therapyLabelLetter
- Sep 24, 2020 Supplement 71 · Efficacy LetterLabel
- Jan 17, 2020 Supplement 68 · Efficacy LabelLetter
- Apr 26, 2019 Supplement 64 · Efficacy · priority review LetterLabelPediatric Medical Review
- Mar 9, 2011 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewSummary ReviewLabel
2 products under this application
- BENLYSTA · BELIMUMAB 400MG · INJECTABLE, INJECTION · Prescription
- BENLYSTA · BELIMUMAB 120MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Belimumab" as an intervention, any sponsor and status, largest first.
- Belimumab Assessment of Safety in SLEPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01705977 · 4,019 participants · Start Nov 27, 2012 · Primary completion Jul 30, 2018
Drug: Placebo plus standard therapy; Belimumab 10 mg/kg plus standard therapy · For: Systemic Lupus Erythematosus
Sites: Anniston, Alabama; Birmingham, Alabama; Huntsville, Alabama · 250 sites in all
- A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)Pivotal-lookingCompleted
Human Genome Sciences Inc.Industry
NCT00424476 · 865 participants · Start May 2007 · Primary completion May 2009
Drug: Placebo; Belimumab 1 mg/kg and 1 more · For: Systemic Lupus Erythematosus
Sites: Buenos Aires, Argentina; La Plata, Argentina; Rosario, Argentina · 92 sites in all
- A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)Pivotal-lookingCompleted
Human Genome Sciences Inc., a GSK CompanyIndustry
NCT01484496 · 839 participants · Start Nov 16, 2011 · Primary completion Feb 13, 2015
Drug: Placebo; Belimumab 200 mg SC and 1 more · For: Systemic Lupus Erythematosus
Sites: Birmingham, Alabama; Peoria, Arizona; Tucson, Arizona · 207 sites in all
- A Study of Belimumab in Subjects With Systemic Lupus ErythematosusPivotal-lookingCompleted
Human Genome Sciences Inc.Industry
NCT00410384 · 819 participants · Start Dec 2006 · Primary completion Sep 2009
Drug: Placebo; Belimumab 1 mg/kg and 1 more · For: Systemic Lupus Erythematosus
Sites: Birmingham, Alabama; Paradise Valley, Arizona; Tucson, Arizona · 146 sites in all
- A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057Pivotal-lookingCompleted
Human Genome Sciences Inc., a GSK CompanyIndustry
NCT00712933 · 738 participants · Start May 30, 2008 · Primary completion Dec 9, 2016
Drug: belimumab · For: Systemic Lupus Erythematosus
Sites: Ciudad Autonoma de Buenos Aires, Argentina; La Plata, Argentina; Rosario, Argentina · 110 sites in all
- GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast AsiaPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01345253 · 709 participants · Start May 23, 2011 · Primary completion Sep 15, 2015
Drug: Belimumab; Placebo · For: Systemic Lupus Erythematosus
Sites: Hefei, China; Guangzhou, China; Harbin, China · 47 sites in all
- A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT06716606 · 514 participants (planned) · Start Dec 12, 2024 · Primary completion Sep 27, 2030
Drug: Belimumab · For: Connective Tissue Diseases
Sites: Los Angeles, California; New York, New York; Philadelphia, Pennsylvania · 41 sites in all
- Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)Pivotal-lookingCompleted
Human Genome Sciences Inc., a GSK CompanyIndustry
NCT01632241 · 503 participants · Start Feb 19, 2013 · Primary completion Jun 18, 2018
Drug: Placebo plus standard therapy; Belimumab 10 mg/kg plus standard therapy and 1 more · For: Systemic Lupus Erythematosus
Sites: Birmingham, Alabama; Covina, California; La Palma, California · 96 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product dose omission issue5,154
- systemic lupus erythematosus3,979
- fatigue2,095
- drug ineffective1,857
- pain1,776
- wrong technique in device usage process1,635
- headache1,593
- nausea1,526
- malaise1,425
- product complaint1,411
- injection site pain1,388
- arthralgia1,380
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 132 |
| 2012 | 893 |
| 2013 | 711 |
| 2014 | 656 |
| 2015 | 1,107 |
| 2016 | 802 |
| 2017 | 1,033 |
| 2018 | 2,166 |
| 2019 | 2,969 |
| 2020 | 2,195 |
| 2021 | 2,402 |
| 2022 | 2,867 |
| 2023 | 3,400 |
| 2024 | 3,817 |
| 2025 | 5,198 |
| 2026 | 1,682 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Benlysta* (Belimumab)
2024 spending
$217M
Beneficiaries
5,831
44,771 claims
Per beneficiary
$37,182
$1,204.92 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $96,759,690 |
| 2021 | $121,887,629 |
| 2022 | $149,755,010 |
| 2023 | $187,011,628 |
| 2024 | $216,806,704 |
Part B: Benlysta (Belimumab) · HCPCS J0490
2024 spending
$126M
Beneficiaries
3,685
30,420 claims
Per beneficiary
$34,064
2024 ASP limit $53.59 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $93,003,577 |
| 2021 | $102,382,337 |
| 2022 | $112,789,686 |
| 2023 | $117,883,242 |
| 2024 | $125,525,139 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
Furie R, Rovin BH, Houssiau F, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Comparative Study
- Belimumab for systemic lupus erythematosus.
Singh JA, Shah NP, Mudano AS · Cochrane Database Syst Rev 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R, Petri M, Zamani O, et al. · Arthritis Rheum 2011 · Clinical Trial, Phase III, Multicenter Study
- Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations.
Kostopoulou M, Mukhtyar CB, Bertsias G, et al. · Ann Rheum Dis 2024 · Systematic Review
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Navarra SV, Guzmán RM, Gallacher AE, et al. · Lancet 2011 · Clinical Trial, Phase III, Multicenter Study
- A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome.
Mariette X, Barone F, Baldini C, et al. · JCI Insight 2022 · Clinical Trial, Phase II, Randomized Controlled Trial
Sponsor: Human Genome Sciences Inc.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.